Minarik, J <br/><br/>
Thalidomide and bortezomib overcome the prognostic significance of proliferative index in multiple myeloma.  [electronic resource] 

 -  Neoplasma  2010 
 - 8-14 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0028-2685 
<br/><br/><label>Standard No.: </label>10.4149/neo_2010_01_008  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents--therapeutic use<br/>Boronic Acids--therapeutic use<br/>Bortezomib<br/>Cell Proliferation<br/>Female<br/>Humans<br/>Male<br/>Middle Aged<br/>Multiple Myeloma--drug therapy<br/>Plasma Cells--pathology<br/>Prognosis<br/>Pyrazines--therapeutic use<br/>Thalidomide--therapeutic use